Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04108026 | Immunotherapy in Patient With Poor General Condition(SAVIMMUNE) | completed | Phase 2 | 50 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04215978 | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 204 | BeiGeneINDUSTRY | 8 | Oct 3, 2025 |
| NCT04631029 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT03833934 | Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance(SPACEWALK) | completed | — | 62 | Addario Lung Cancer Medical InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05386888 | A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC | completed | Phase 2 | 65 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06199050 | The Effect of 360° Virtual Reality Movies on Fear and Anxiety(ENGAGE) | completed | N/A | 292 | Maastricht Radiation OncologyOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05775796 | Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013) | completed | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07201077 | ArticuGrasp Trial: New Flexible Tool vs Standard Grasper for Lung Cancer Node Removal in Keyhole Chest Surgery | completed | N/A | 100 | Jianxing HeOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT01172314 | Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients | completed | N/A | 41 | Texas A&M UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04885998 | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | completed | Phase 1 | 23 | AmgenINDUSTRY | 6 | Sep 29, 2025 | clinicaltrials |
| NCT02111681 | Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer | completed | N/A | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT03041311 | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC | completed | Phase 2 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT03184571 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 99 | BerGenBio ASAINDUSTRY | 4 | Sep 25, 2025 | clinicaltrials |
| NCT04589247 | Improving Cancer On-treatment Symptom Management(IMPROVE) | completed | — | 104 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04681131 | CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | completed | Phase 2 | 85 | BioAtla, Inc.INDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT02719847 | EBUS TBNA After PET/CT in Diagnosing Patients With Stage I-IIA Non-small Cell Lung Cancer Evaluated for Stereotactic Body Radiation Therapy | completed | — | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT03801902 | Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07186855 | Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC | completed | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT01812031 | Benefits Study of Respiratory-gated PET Acquisition in Lung Disease(PneumoTEP) | completed | N/A | 103 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06261294 | OncoSweep Cancer Spotlight and Spectrum Product Line | completed | — | 109 | Pharus Taiwan, Inc.INDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05014815 | Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 272 | BeiGeneINDUSTRY | 8 | Sep 16, 2025 | clinicaltrials |
| NCT02493114 | Physical Functioning Throughout Lung Cancer Treatment(LUCAT) | completed | — | 150 | Hasselt UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04575025 | Special Drug Use-results Surveillance of Tabrecta Tablets | completed | — | 109 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | completed | Phase 1 | 89 | Tempest TherapeuticsINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT03786653 | Feasibility of Immunotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting (ImHADom)(ImHADom) | completed | — | 10 | RENAULT Patrick AldoOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05219162 | Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).(GPS) | completed | Phase 4 | 182 | AstraZenecaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT03653546 | First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases(BM) | completed | Phase 2 / Phase 3 | 492 | Alpha Biopharma (Jiangsu) Co., Ltd.INDUSTRY | 4 | Sep 10, 2025 | clinicaltrials |
| NCT04694846 | Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use | completed | N/A | 19 | Thomas Jefferson UniversityOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04221529 | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide(SPACE) | completed | Phase 2 | 70 | AIO-Studien-gGmbHOTHER | 2 | Sep 8, 2025 | clinicaltrials |
| NCT05867953 | Assessment of Tool Placement in Pulmonary Nodule(s) Using a Robotic Navigational Bronchoscopy System | completed | N/A | 200 | Intuitive SurgicalINDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04853017 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors(AMPLIFY-201) | completed | Phase 1 | 25 | Elicio TherapeuticsINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03844464 | Safety and Efficacy of Lorbrena | completed | — | 1,290 | PfizerINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04879849 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | completed | Phase 1 | 34 | TakedaINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06952894 | Feasibility of RUS Lung in MITS(HTL-001) | completed | N/A | 34 | Hutom CorpINDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06207435 | Community Support Program for Lung Cancer Screening(LCS) | completed | N/A | 242 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | completed | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05509699 | Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 21 | Hutchison Medipharma LimitedINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05815862 | Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer | completed | Phase 2 | 29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT03977467 | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | completed | Phase 2 | 46 | SCRI Development Innovations, LLCOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06582849 | Enhanced Assistance During Radiotherapy for Unmet Essential Needs(EARN) | completed | N/A | 33 | Washington University School of MedicineOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT02735746 | Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis(HFFLI) | completed | — | 60 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT02819024 | Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography | completed | N/A | 6 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT03322540 | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | completed | Phase 2 | 154 | Incyte CorporationINDUSTRY | 18 | Aug 22, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05517083 | Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer | completed | N/A | 41 | Pusan National University HospitalOTHER | 1 | Aug 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 3, 2025source: clinicaltrials